natgillin/translations-raw huggingface dataset:
In a placebo-controlled trial of RSV disease prophylaxis in (IMpact-RSV trial) 1502 high-risk children (1002 Synagis; 500 placebo), 5 monthly doses of 15 mg/kg reduced the incidence of RSV related hospitalisation by 55% (p = < 0.001).
Študije, v katerih so uporabljali palivizumab v liofilizirani oblikiV preskušanju profilakse bolezni RSV, kontroliranem s placebom, (preskušanje IMpact-RSV) pri 1.502 zelo ogroženih bolnikih (1.002 sta dobivala zdravilo Synagis, 500 placebo) je 5 mesečnih odmerkov 15 mg/kg zmanjšalo incidenco hospitalizacij zaradi RSV za 55% (p = < 0,001).
When using Palivizumab 100 mg/1 ml, the volume (expressed in ml) of Palivizumab to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Ko se uporablja palivizumab 100 mg/1 ml, je potrebna količina palivizumaba (izražena v ml), ki se injicira v enomesečnih intervalih = (bolnikova telesna masa v kg) pomnožena z 0,15
Lyophilised formulation of palivizumab
Palivizumab v tekoči obliki
Palivizumab is administered intramuscularly, preferably in the anterolateral aspect of the thigh.
Palivizumab se injicira intramuskularno, po možnosti v anterolateralni predel stegna.
Synagis is presented as a powder and solvent for solution for injection (50 mg of powder in vial) + 1 ml of solvent in ampoule - Pack size of 1.
Zdravilo Synagis sestavljata prašek in vehikel za raztopino za injiciranje (50 mg praška v viali) + 1 ml vehikla v ampuli - pakiranje vsebuje 1 vialo in 1 ampulo.
Administrator's Instructions
Navodila za zdravstveno osebje
Uncommon (affects less than 1 users in 100): fits hives
Občasni (pojavijo se pri manj kot 1 bolniku od 100 bolnikov):
Do not dilute the product.
Zdravila ne redčite.
Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection Active substance: palivizumab
Synagis 50 mg/0,5 ml raztopina za injiciranje Synagis 100 mg/1 ml raztopina za injiciranje učinkovina: palivizumab
Synagis 50 mg vial label
Synagis 50 mg - nalepka na viali
Common adverse reactions occurring with palivizumab are fever, rash and injection site reaction.
Pogosti neželeni učinki, ki se pojavijo pri palivizumabu so povišana telesna temperatura, izpuščaj in reakcije na mestu injiciranja.
Also contains: histidine, glycine and mannitol.
Vsebuje tudi: histidin, glicinin manitol.
Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection
Synagis 50 mg/0,5 ml raztopina za injiciranje Synagis 100 mg/1 ml raztopina za injiciranje
When using Palivizumab 100 mg/ml, the volume (expressed in ml) of Palivizumab to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Ko se uporablja palivizumab 100 mg/ml, je potrebna količina palivizumaba (izražena v ml), ki se injicira v enomesečnih intervalih = (bolnikova telesna masa v kg) pomnožena z 0,15
The powder is a white to off-white cake.
Prašek je bel do sivo bel z enakomernimi delci.
1 ml of Synagis solution contains 100 mg of palivizumab*.
1 ml raztopine zdravila Synagis vsebuje 100 mg palivizumaba*.
Intramuscular use.
intramuskularna uporaba viala za enkratno uporabo
The volume (expressed in ml) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15.
Količina palivizumaba (izražena v ml), ki jo je potrebno injicirati v enomesečnih intervalih = [telesna masa bolnika v kg] pomnožena z 0,15.
Allergic reactions including very rare cases of anaphylaxis and anaphylactic shock have been reported following palivizumab administration.
Po aplikaciji palivizumaba so bile opisane alergijske reakcije in anafilaktični šok, vključno z zelo redkimi primeri anafilaksije.
Each 0.5 ml vial contains 50 mg of palivizumab.
Ena 0,5 ml viala vsebuje 50 mg palivizumaba.
Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays.
Palivizumab ne moti testov, ki temeljijo na metodi obratne transkripcije in verižne reakcije s polimerazo (RT-PCR).
Synagis 100 mg/1 ml solution for injection palivizumab
Synagis 100 mg/1 ml raztopina za injiciranje palivizumab
Take special care with Synagis if your child is unwell.
Bodite posebno pozorni pri uporabi zdravila Synagis
- Each 1 ml vial contains 100 mg of palivizumab.
- Vsaka 1 ml viala vsebuje 100 mg palivizumaba.
How to store Synagis
Shranjevanje zdravila Synagis
To administer, remove the tab portion of the vial cap and clean the stopper with 70 % ethanol or equivalent.
Za uporabo odstranite del z zanko na pokrovčku viale in očistite zamašek s 70 % etanolom ali ekvivalentom.
Synagis 50 mg/0.5 ml solution for injection palivizumab
Synagis 50 mg/0,5 ml raztopina za injiciranje palivizumab
Among 139 children in the congenital heart disease study receiving palivizumab who had cardio-pulmonary bypass and for whom paired serum samples were available, the mean serum palivizumab concentration was approximately 100 g/ml pre-cardiac bypass and declined to approximately 40 g/ml after bypass.
Pri teh 139 otrocih je bila povprečna koncentracija palivizumaba v serumu pred zunajtelesnim obtokom približno 100 g/ml, po njem pa se je zmanjšala na približno 40 g/ml.
To reconstitute, remove the tab portion of the vial cap and clean the rubber stopper with 70% ethanol or equivalent.
Za rekonstitucijo odstranite del z zanko na pokrovčku viale in očistite kavčukovo zaporko s 70% etanolom ali ekvivalentom.
Adverse reactions both clinical and laboratory, are displayed by system organ class and frequency (very common ≥ 1/10; common ≥ 1/100 to < 1/10; uncommon ≥ 1/1,000 to < 1/100 ; rare ≥ 1/10,000 to < 1/1,000) in studies conducted in premature and bronchopulmonary dysplasia paediatric patients, and paediatric congenital heart disease patients.
Klinični in laboratorijski neželeni učinki, so prikazani v naslednjih tabelah po organskih sistemih in pogostnosti (zelo pogosti ≥1/10; pogosti  1/100 do  1/10; občasni  1/1.000 do  1/100; redki ≥ 1/10.000 do < 1/1.000).
Adverse reactions both clinical and laboratory, are displayed by system organ class and frequency (very common ≥ 1/10; common ≥ 1/100 to < 1/10; uncommon ≥ 1/1,000 to < 1/100; rare ≥ 1/10,000 to <1/1,000 ) in studies conducted in premature and bronchopulmonary dysplasia paediatric patients, and paediatric congenital heart disease patients.
Klinični in laboratorijski neželeni učinki so prikazani v naslednjih tabelah po organskih sistemih in pogostnosti (zelo pogosti ≥ 1/10; pogosti  1/100 do 1/10; občasni  1/1.000 do  1/100; redki ≥ 1/10.000 do < 1/1.000).
To reconstitute, remove the tab portion of the vial cap and clean the rubber stopper with 70% ethanol or equivalent
Za rekonstitucijo odstranite del z zanko na pokrovčku viale in očistite kavčukovo zaporko z 70% etanolom ali ekvivalentom.
Synagis 100 mg powder and solvent for solution for injection Active substance: palivizumab
Synagis 100 mg prašek in vehikel za raztopino za injiciranje učinkovina: palivizumab
Each vial contains: 100 mg palivizumab, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Ena viala vsebuje: 100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ml.
When reconstituted as recommended the final concentration is 100 mg/ml.
Koncentracija po navodilu pripravljene raztopine palivizumaba je 100 mg/ml.
Outer Carton of 0.5 ml vial
Škatla z 0,5 ml vialo
Solvent for Synagis
Vehikel za zdravilo Synagis
Synagis 50 mg powder and solvent for solution for injection Active substance: palivizumab
Synagis 50 mg prašek in vehikel za raztopino za injiciranje učinkovina: palivizumab
Liquid formulation of palivizumab
Palivizumab v liofilizirani obliki
Each 1 ml vial contains 100 mg of palivizumab.
Ena 1 ml viala vsebuje 100 mg palivizumaba.
Synagis is a white to off-white cake.
Zdravilo Synagis je bel do sivo bel prašek z enakomernimi delci.
Synagis 100 mg powder and solvent for solution for injection
Synagis 100 mg prašek in vehikel za raztopino za injiciranje
Synagis 50 mg powder and solvent for solution for injection
Synagis 50 mg prašek in vehikel za raztopino za injiciranje
The possible risk of enhanced RSV infection in the season following the season in which the patients were treated with palivizumab has not been conclusively ruled out by studies performed aiming at this particular point.
Učinkovitost palivizumaba pri bolnikih, ki ga dobijo v ponovnem ciklusu naslednjo sezono RSV, ni bila formalno preskušena v kakšni študiji, opravljeni s tem namenom.
Each vial contains 50 mg palivizumab, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Ena viala vsebuje 50 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ml.
- Each 0.5 ml vial contains 50 mg of palivizumab.
- Vsaka 0,5 ml viala vsenbuje 50 mg palivizumaba.
Synagis 50 mg powder and solvent for solution for injection palivizumab
Synagis 50 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 100 mg powder and solvent for solution for injection palivizumab
Synagus 100 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 50 mg powder for solution for injection palivizumab
Synagis 50 mg prašek za raztopino za injiciranje palivizumab i.m.
(3 x 0.15) ml = 0.45 ml palivizumab per month
Na primer, za dojenčka s telesno maso 3 kg velja naslednji izračun: (3 x 0,15) ml = 0,45 ml palivizumaba na mesec
Synagis 100 mg powder for solution for injection palivizumab
Synagis 100 mg prašek za raztopino za injiciranje palivizumab i.m.
Common (affects 1 to 10 users in 100): pain, redness or swelling at the injection site a pause in breathing or other breathing difficulties
Pogosti (pojavijo se pri 1 do 10 bolnikih od 100 bolnikov):
Other information about Tekturna:
Druge informacije o zdravilu Tekturna:
The European Commission granted a marketing authorisation valid throughout the European Union for Tekturna to Novartis Europharm Limited on 22 August 2007.
Evropska komisija je dovoljenje za promet z zdravilom Tekturna, veljavno po vsej Evropski uniji, odobrila družbi Novartis Europharm Limited dne 22. avgusta 2007.
Tekturna is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group.
Zdravilo Tekturna ni priporočeno za uporabo pri bolnikih, mlajših od 18 let, zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej starostni skupini.
The Committee recommended that Tekturna be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Tekturna odobri dovoljenje za promet.
The effects of Tekturna were first tested in experimental models before being studied in humans.
Učinki zdravila Tekturna so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Tekturna.
Vzeti ga je treba z lahkim obrokom, najbolje vsak dan ob istem času, vendar pa se zdravilo Tekturna ne sme vzeti skupaj s sokom grenivke.
What benefit has Tekturna shown during the studies?
Kakšne koristi je zdravilo Tekturna izkazalo med študijami?
Tekturna was studied in 14 main studies involving over 10,000 patients with essential hypertension.
Zdravilo Tekturna so raziskali v 14 glavnih študijah, v katere je bilo vključeno več kot 10 000 bolnikov z esencialno hipertenzijo.
Tekturna is used to treat essential hypertension (high blood pressure).
Zdravilo Tekturna se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka).
What is the risk associated with Tekturna?
Kakšna tveganja so povezana z zdravilom Tekturna?
The recommended dose of Tekturna is 150 mg once a day, either taken alone or in combination with other medicines for hypertension.
Priporočeni odmerek zdravila Tekturna znaša 150 mg enkrat na dan, bodisi samostojno ali v kombinaciji z drugimi zdravili za zdravljenje hipertenzije.
The studies also showed that Tekturna, when taken in combination with other medicines (especially hydrochlorothiazide), can produce additional decreases in blood pressure compared with the decreases produced by these medicines when they are taken without Tekturna.
Študije so pokazale tudi, da lahko zdravilo Tekturna v kombinaciji z drugimi zdravili (še zlasti hidroklorotiazidom) povzroči še dodatna znižanja krvnega tlaka v primerjavi z znižanji tlaka, ki jih imajo ta zdravila, če se jemljejo brez zdravila Tekturna.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TEKTURNA EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) TEKTURNA Povzetek EPAR za javnost
The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic).
Študije so trajale od šest do 52 tednov, glavno merilo učinkovitosti pa je bila sprememba krvnega tlaka med mirovalno fazo srčnega utripa (diastolični tlak) ali med krčenjem komor srca (sistolični tlak).
The most common side effect with Tekturna (seen in between 1 and 10 patients in 100) is diarrhoea.
Najpogostejši neželeni učinek zdravila Tekturna (opažen pri 1 do 10 bolnikih izmed 100) je driska.
Tekturna also reduced blood pressure in patients with diabetes and patients who were overweight.
Zdravilo Tekturna je krvni tlak znižalo tudi pri bolnikih s sladkorno boleznijo in bolnikih s prekomerno težo.
When the results of the five studies comparing Tekturna taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Tekturna, from an average of 99.4 mmHg at the start of the study.
Ko so primerjali skupaj rezultate petih študij, v katerih so zdravilo Tekturna kot samostojno zdravilo primerjali s placebom, se je pri bolnikih, mlajših od 65 let, po osmih tednih jemanja 150 mg zdravila Tekturna povprečni diastolični tlak, ki je na začetku znašal 99,4 mmHg, v povprečju znižal za 9,0 mmHg.
It must not be in patients who have had angioedema (swelling under the skin) with aliskiren or in women who are more than three months pregnant.
Ne sme se uporabljati pri bolnikih, pri katerih se je zaradi jemanja aliskirena pojavil angioedem (podkožno otekanje), ali pri ženskah, ki so noseče več kot tri mesece.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Tekturna are greater than its risks for the treatment of essential hypertension.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tekturna pri zdravljenju esencialne hipertenzije večje od z njim povezanih tveganj.
Tekturna should not be used by people who may be hypersensitive (allergic) to aliskiren or any of the other ingredients.
Zdravila Tekturna ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) aliskiren ali katero koli drugo sestavino zdravila.
For the full list of all side effects reported with Tekturna, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tekturna, glejte navodilo za uporabo.
Tekturna is a medicine that contains the active substance aliskiren.
Tekturna je zdravilo, ki vsebuje zdravilno učinkovino aliskiren.
Tekturna must also not be taken with ciclosporin (a medicine that reduces the activity of the immune system), quinidine (used to correct irregular heartbeat) or verapamil (used to treat heart problems).
Zdravilo Tekturna se prav tako ne sme jemati s ciklosporinom (zdravilom, ki zmanjšuje dejavnost imunskega sistema), kinidinom (zdravilom za odpravljanje motenj srčnega ritma) ali verapamilom (zdravilom za zdravljenje težav s srcem).
Why has Tekturna been approved?
Zakaj je bilo zdravilo Tekturna odobreno?
Combination studies looked at Tekturna used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
V študijah kombinacij zdravil so zdravilo Tekturna proučevali v kombinaciji z zaviralcem angiotenzinske konvertaze (ramiprilom), zaviralcem angiotenzinskih receptorjev (valsartanom), zaviralcem receptorjev beta (atenololom), zaviralcem kalcijevih kanalčkov (amlodipinom) in diuretikom (hidroklorotiazidom).
Tekturna, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Zdravilo Tekturna so kot samostojno zdravilo ali v kombinaciji z drugimi zdravili primerjali tudi z drugimi zdravili za zdravljenje hipertenzije.
Tekturna on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Zdravilo Tekturna kot samostojno zdravilo je bilo pri zdravljenju visokega krvnega tlaka učinkovitejše od placeba in enako učinkovito kot zdravljenje s primerljivimi zdravili.
Larger falls were seen in patients aged 65 years or over and those taking higher doses of Tekturna.
Pri bolnikih, starih 65 let ali več, in tistih, ki so jemali večje odmerke zdravila Tekturna, so opazili večja znižanja tlaka.
The full EPAR for Tekturna can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tekturna je na voljo tukaj.
The active substance in Tekturna, aliskiren, is a renin inhibitor.
Zdravilna učinkovina zdravila Tekturna, aliskiren, spada med zaviralce renina.
How has Tekturna been studied?
Kako je bilo zdravilo Tekturna raziskano?
What is Tekturna used for?
Za kaj se zdravilo Tekturna uporablja?
What is Tekturna?
Kaj je zdravilo Tekturna?
How is Tekturna used?
Kako se zdravilo Tekturna uporablja?
The dose of Tekturna may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Pri bolnikih, katerih krvni tlak ni primerno nadzorovan, se lahko odmerek zdravila Tekturna poveča na 300 mg enkrat na dan.
How does Tekturna work?
Kako zdravilo Tekturna deluje?
In five of the studies, the effects of Tekturna taken alone were compared with those of placebo (a dummy treatment).
Tekturna, uporabljenega kot samostojno zdravilo, primerjali s placebom (zdravilom brez zdravilne učinkovine).
Each transdermal patch releases 203 micrograms of NGMN and 33.9 micrograms of EE per 24 h.
Iz vsakega transdermalnega obliža se sprostijo 203 mikrogrami NGMN in 33,9 mikrogramov EE v 24 urah.
Each transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
En transdermalni obliž vsebuje 6 mg norelgestromina (NGMN) in 600 mikrogramov etinilestradiola (EE).
The company will also provide an educational plan for doctors and patients.
Pripravila bo tudi izobraževalni načrt za zdravnike in bolnike.
The European Commission granted a marketing authorisation valid throughout the European Union for Intrinsa on 28 July 2006.
Evropska komisija je dovoljenje za promet z zdravilom Intrinsa, veljavno po vsej Evropski uniji, odobrila dne 28. julija 2006.
The marketing authorisation holder is Warner Chilcott UK Ltd.
Imetnik dovoljenja za promet z zdravilom je družba Warner Chilcott UK Ltd.
The patch remains on the skin for three or four days and is then replaced by a new patch in a different place.
Obliž ostane na koži tri ali štiri dni, nato pa se ga nadomesti z novim na drugem mestu.
The main measure of effectiveness was based on the change in the questionnaire score before the study began and after six months of treatment.
Glavno merilo učinkovitosti je temeljilo na spremembi v rezultatu vprašalnika pred začetkom študije in po šestih mesecih zdravljenja z zdravilom.
Intrinsa was more effective than placebo.
Zdravilo Intrinsa je bilo učinkovitejše od placeba.
Other information about Intrinsa:
Druge informacije o zdravilu Intrinsa:
The marketing authorisation is valid for five years, after which it can be renewed.
Dovoljenje za promet z zdravilom velja pet let, nato pa ga je mogoče podaljšati.
Because testosterone is a well-known substance that is already used in other medicines, the company used data from the published literature as well as carrying out studies itself.
Glede na dejstvo, da je testosteron dobro znana učinkovina, ki se uporablja tudi v drugih zdravilih, je družba uporabila podatke iz objavljene literature, izvedla pa je tudi lastne študije.
The CHMP decided that Intrinsa's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Intrinsa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
This document is a summary of the European public assessment report (EPAR) for Intrinsa.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Intrinsa.
If a patient does not feel any improvement after three to six months of treatment, she should contact her doctor and have her treatment reviewed.
Bolnica, ki po treh do šestih mesecih zdravljenja ne začuti izboljšanja, naj se posvetuje s svojim zdravnikom, ki naj ponovno presodi primernost zdravljenja.
For more information about treatment with Intrinsa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Intrinsa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Intrinsa is used as a continuous treatment, as one patch twice a week.
Zdravilo Intrinsa se uporablja za kontinuirano zdravljenje z aplikacijo enega obliža dvakrat tedensko.
The two main studies involved 1,095 women with an average age of 49 years who received Intrinsa for up to a year.
V dveh glavnih študijah je sodelovalo 1 095 žensk povprečne starosti 49 let, ki so uporabljale zdravilo Intrinsa v obdobju do enega leta.
The studies used a specially designed questionnaire to measure sexual interest and activity by recording the number of satisfying sexual episodes in a four-week period.
V študijah je bil uporabljen posebej oblikovan vprašalnik, s katerim so na podlagi beleženja števila zadovoljivih spolnih odnosov v štiritedenskem obdobju merili spolno zanimanje in spolne aktivnosti.
Low testosterone levels have been linked to low sexual desire and to reduced sexual thoughts and arousal.
Nizka raven testosterona je povezana z nizkim spolnim poželenjem in zmanjšanjem spolnih misli in spolnega vzburjenja.
What benefit has Intrinsa shown during the studies?
Kakšne koristi je zdravilo Intrinsa izkazalo med študijami?
It is used in patients already taking an oestrogen (a female
Uporablja se pri bolnicah, ki že jemljejo estrogen (ženski spolni hormon).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Intrinsa.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Intrinsa, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The active substance in Intrinsa, testosterone, is a natural sex hormone produced in men and, to a lesser extent, in women.
Zdravilna učinkovina v zdravilu Intrinsa, testosteron, je naravni spolni hormon, ki se tvori pri moških in v manjši meri pri ženskah.
In contrast, women who used placebo had around four episodes in a four-week period after six months.
Nasprotno pa so ženske, ki so prejemale placebo, imele po šestih mesecih okoli štiri spolne odnose v štiritedenskem obdobju.
The company will review all of the ongoing studies with Intrinsa to look at potential long-term risks including breast cancer, endometrial cancer (cancer of the lining of the womb) and side effects affecting the heart and blood vessels.
Družba bo pregledala vse potekajoče študije z zdravilom Intrinsa z namenom proučitve morebitnih dolgoročnih tveganj, ki vključujejo rak dojke, rak endometrija (rak maternične sluznice) in neželene učinke, ki vplivajo na srce in ožilje.